Basser Executive Director Susan Domchek, MD, discusses a new resource with JAMA that may help guide clinical decision-making related to BRCA genetic mutations.

Basser Center Executive Director Susan Domchek, MD, discusses the complex issue of risk-reducing mastectomy in BRCA mutation carriers in an editorial for the Journal of the American Medical Association.

The Basser Center's Young Leadership Council recently hosted a storytelling event featuring personal stories from three individuals touched by BRCA mutations, which all spoke to the promising future that research will provide for future patients and the newly BRCA-positive population. 

Basser Center Executive Director Susan Domchek, MD, joins KJZZ's The Show for an episode devoted to genetic testing, preventative surgery, and raising awareness of hereditary breast cancer.

Basser Young Leadership Council member Suzanne Zupello recently penned this personal piece on the importance of support communities for those with BRCA mutations for The Lily.

Basser Executive Director, Susan Domchek, MD, explains the recently began BRCA Founder Outreach Study (BFOR) with the Cleveland Jewish News.

Basser Executive Director, Susan Domchek, MD, discusses the challenges of treating pancreatic cancer, the role of BRCA mutations in malignancies other than breast or ovarian cancers, and the broader role of PARP inhibitors for this patient population.

Rates of inherited mutations in genes other than BRCA are twice as high in breast cancer patients who have had a second primary cancer – including, in some cases, different types of breast cancer – compared to patients who have only had a single breast cancer. 

A targeted therapy that has shown its power in fighting ovarian cancer in women, including those with BRCA1 and BRCA2 mutations, may also help patients with aggressive pancreatic cancer who harbor these mutations and have few or no other treatment options.